
A guide to sky-watching from summer to autumn
Between now and the autumnal equinox, we are treated to the ghostly beauty of the summer Milky Way, a spectacular conjunction of the two brightest planets in the sky and the annual display of the Perseids meteor shower.
Astronomical summer begins with the summer solstice, which was officially marked on June 20 at 10:42 p.m. Eastern time.
This moment marked the Sun's highest excursion into the Northern Hemisphere sky, and for residents in the northern half of the globe, it brings the shortest nights of the year.
Here in Washington we experience 9 hours and 6 minutes between sunset and sunrise for a couple of days on either side of the 20th day. Due to the slightly elliptical shape of Earth's orbit around the sun, we have already experienced the year's earliest sunrise, but the latest sunset won't occur until June 27, when Old Sol slips below the horizon at 8:38 p.m. Eastern time.
The summer solstice has been an important calendar marker for humans for thousands of years. Evidence of this is found in ancient monuments and sacred sites throughout the earliest recorded histories of early civilizations.
Perhaps the most famous of these is Stonehenge in England, a site occupied and developed by neolithic people over the course of a thousand years. It began around 3100 B.C. as a simple circular trench cut into the chalk of the Salisbury plains, with a long trench pointing to the direction of midsummer sunrise. The stone structure that we now see was added over the next millennium, turning the site into a sophisticated astronomical computer to determine the equinoxes and solstices.
From ancient Mesopotamia to the Desert Southwest of the United States and sites in Mesoamerica, the importance of observing the solstice and related phenomena was vital to the survival of our distant ancestors.
There will be three full moons during this season. They will fall on July 10, Aug. 9 and Sept. 7.
July's full moon is known as the buck moon since male deer and other related species begin to grow antlers for the fall mating season. It is also known as the thunder moon due to the typical weather of midsummer afternoons.
August brings us the sturgeon moon, so named because of the great number of these large fish that are found in the Great Lakes at this time of the year.
September's full moon is usually dubbed the harvest moon, but this year that title belongs to October's full moon, which occurs closest to the autumnal equinox. This year the full moon of September is the corn moon, a celebration of one of the most important crops in the annual harvest.
The corn moon will offer residents of Europe, Africa and especially Asia a total lunar eclipse.
Unfortunately this event won't be visible from any part of the United States, but we won't have to wait too long to see one from our shores — mark your calendars for the early morning hours of March 3, 2026.
Summer begins with only one planet in the evening sky: Mars.
The Red Planet is wending its way eastward among the stars of spring in the western sky. On the night of the solstice, Mars may be found just east of the bright star Regulus in the constellation of Leo, the lion. By mid-September it will be close to the bright blue star Spica in Virgo as evening twilight falls.
Night owls will find Saturn rising in the east after midnight in late June. By mid-August, the ringed planet rises at the end of evening twilight and is the prominent yellow-hued glow below the 'great square' asterism of Pegasus.
By the time of the equinox, Saturn will be an easy evening target for telescope owners. This is a particularly interesting time to view Saturn, as it underwent one of its own equinoxes back on May 6. This occurs twice in its 30-year trek around the sun, and when the sun crosses the plane of Saturn's rings, they effectively disappear.
Through the telescope, the rings will appear as spikes on either side of the planet, gradually becoming thinner into the fall as Earth approaches their orbital plane.
The two brightest planets, Venus and Jupiter, remain in the morning sky throughout the season. Venus rises at around 3:30 p.m. Eastern time and is a bright beacon in the gathering morning twilight. Jupiter enters the morning sky in early August to join Venus, and on the morning of Aug. 12, the pair are less than one degree apart. A week later, Mercury will appear low in the east below the bright pair.
The morning hours of Aug. 12 will put on quite a show.
In addition to the conjunction of Venus and Jupiter, Saturn will be just to the east of the waning gibbous moon. The latter puts something of a damper on the annual Perseids meteor shower, but if you're on vacation at a dark site — like the beach or the mountains — take some time to see if you can spot some of the shower's brighter members.
Many of the Perseids are like fireballs that can appear as bright as Jupiter or Venus. You might have to wait about 10 to 15 minutes to see one, but when you do it's quite a show.
The summer sky has a number of bright stars that form easily recognizable patterns.
The easiest of these to spot are the members of the summer triangle, consisting of Vega, Altair and Deneb. Each of these stars lead their own constellations, with the most distinctive being Cygnus, the Swan, where Deneb marks its 'tail.' The Swan's 'head' is marked by a gold-hued star that lies almost in the middle of the triangle. This is Albireo, perhaps the most beautiful double star in the sky. It can be resolved with almost any telescope, and the color contrast between its blue and yellow components is striking.
You'll notice the luminous band of the summer Milky Way piercing the heart of the triangle on a moonless night from a dark location. Follow it to the south to locate the constellation of Scorpius with its distinctive red star Antares. A clear southern horizon will reveal the constellation's namesake shape.
To the east of the Scorpion, look for the 'teapot' asterism of the constellation Sagittarius, the Archer. Use binoculars to pan northward from the teapot's 'spout' to reveal star clusters and glowing gaseous nebulae — this is my favorite place to spend those summer nights.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
6 hours ago
- Yahoo
Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'
Kumail Nanjiani said that Elon Musk was "upset" with the opening scene of Silicon Valley. Nanjiani appeared on an episode of Mike Birbiglia's podcast Working It Out, where he recalled some of the experiences he had with tech giants while on the show. "He didn't like the show," Nanjiani said of Musk. The Eternals actor remembered meeting the Tesla CEO, who said the parties he attended were "much cooler" than those depicted on Silicon Valley. The premiere opens with Kid Rock playing at a tech event to a sparse, dead crowd. "It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'" the Big Sick star said. The comedian also met Mark Zuckerberg while doing the show, but made a bad impression. He and his costar Martin Starr had presented at the Breakthrough Awards, which were co-founded by Zuckerberg, in 2016. During the ceremony, the Silicon Valley actors called back to a joke from the season 1 finale about giving hand jobs to an entire conference room of people. They retooled that bit to accommodate the number of scientists at the Breakthrough Awards and bombed. Nanjiani said he doesn't blame the Facebook founder for disliking him after that moment. "He was like, 'What the f--- was that?'" Nanjiani said. "And truly in that moment he was right." Check out the full episode of Working It Out with Kumail Nanjiani below. Read the original article on Entertainment Weekly


CNN
9 hours ago
- CNN
On GPS: The Trump administration's war on science
Secretary of Health and Human Services Robert F. Kennedy Jr. announced that he is cutting nearly half a billion dollars in federally funded mRNA vaccine research. Fareed speaks with former Baltimore Health Commissioner Dr. Leana Wen about the promises of mRNA technology for treating infectious diseases and the impact of cuts on America's scientists.